This HTML5 document contains 30 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/drugbank/drug/DB06720/identifier/kegg-drug/
n19http://linked.opendata.cz/resource/drugbank/drug/DB06720/identifier/drugbank/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n15http://linked.opendata.cz/resource/drugbank/drug/DB06720/identifier/national-drug-code-directory/
n17http://www.drugs.com/
n18http://www.rxlist.com/
n7http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/patent/
n11http://linked.opendata.cz/resource/drugbank/drug/DB06720/identifier/uniprotkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n13http://linked.opendata.cz/resource/drugbank/drug/DB06720/identifier/wikipedia/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/atc/
n21http://www.pdrhealth.com/info/v1us/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06720
rdf:type
n3:Drug
n3:description
Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease.
n3:dosage
n4:271B5151-363D-11E5-9242-09173F13E4C5 n4:271B5150-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Pastores GM: Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease. Curr Opin Investig Drugs. 2010 Apr;11(4):472-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20336596 # Vairo F, Netto C, Dorneles A, Mittelstadt S, Wilke M, Doneda D, Michelin K, Ribeiro CB, Quevedo A, Vieira T, Nalin T, Lueska S, Schwartz IV: Enzyme Replacement Therapy in a Patient with Gaucher Disease Type III: A Paradigmatic Case Showing Severe Adverse Reactions Started a Long Time After the Beginning of Treatment. JIMD Rep. 2013 Feb 21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23430813
n3:group
investigational approved
n3:halfLife
11-12 minutes.
n3:indication
Velaglucerase alfa is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for pediatric and adult patients with type 1 Gaucher disease.
owl:sameAs
n7:DB06720
dcterms:title
Velaglucerase alfa
adms:identifier
n11:P04062 n13:Velaglucerase_alfa n14:D09029 n15:54092-701-04 n19:DB06720
n3:mechanismOfAction
Velaglucerase alfa catalyzes the hydrolysis of glucocerebroside, reducing the amount of accumulated glucocerebroside.
n3:patent
n12:7138262
n3:synonym
Imiglucerase VPRIV
n3:volumeOfDistribution
The mean volume of distribution at steady state ranges from 82 to 108 mL/kg (8.2% to 10.8% of body weight).
foaf:page
n17:vpriv.html3 n18:vpriv-drug.htm n21:vpriv
n3:Molecular-Formula
n5:271B5153-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B5152-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n9:A16AB10
n3:casRegistryNumber
884604-91-5
n3:category
n3:clearance
Mean clearance ranges from 6.72 to 7.56 mL/min/kg.